GlassScriptPhysician profile
Alfred Luk
NPI 1902190978
$798.26
in general payments reported to CMS, 2019-2025
15 companies · $39.09 in 2025
The $39.09 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.88 · 2020: $30.00 · 2021: $47.20 · 2022: $28.13 · 2023: $222 · 2024: $367 · 2025: $39.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $196.27 | 2023-2024 | Rezzayo, Vabomere, Kimyrsa |
| Astellas Pharma US INC | $141.74 | 2021-2025 | Cresemba |
| Abbvie INC. | $124.91 | 2024 | |
| Paratek Pharmaceuticals, INC. | $70.54 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $51.45 | 2019-2024 | Recarbrio, Prevymis, Zerbaxa |
| Organon LLC | $37.86 | 2021-2023 | Nexplanon |
| Merz North America, INC. | $30.00 | 2020 | |
| Progenics Pharmaceuticals, INC. | $28.64 | 2024 | |
| Aurinia Pharma U.S., INC. | $28.13 | 2022 | |
| Viiv Healthcare Company | $20.34 | 2023 | Cabenuva |
| Agios Pharmaceuticals, INC. | $19.75 | 2019 | |
| Tesaro, INC. | $19.70 | 2019 | |
| Invivyd INC | $16.98 | 2025 | Pemgarda |
| Janssen Biotech, INC. | $11.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Luk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.